Grant Boldt
Chief Operating Officer CPTx
As Chief Operating Officer of CPTx, Dr. Grant Boldt leads the company’s innovation-driven R&D in next-generation genetic medicines, guiding programs from discovery and design through delivery, manufacturing, and preparation for first-in-human studies. His role integrates scientific vision with organizational leadership to advance pioneering approaches in genetic medicine. Dr. Boldt joined CPTx in early 2024, bringing decades of experience at the intersection of biotechnology R&D and pharmaceutical manufacturing strategy. He previously served as Vice President of Research Pharmaceuticals at Sigma-Aldrich, Senior Vice President and Business Unit Head of Biologics at Lonza, and Executive Vice President of Biologics at Avantor. Over the course of his career, he has authored numerous scientific publications and patents and has been a frequent speaker, with a consistent focus on translating innovative science into transformative therapeutic applications. Dr. Boldt received his PhD in Chemical Biology from Scripps Research Institute, CA, US.
Seminars
- Explore how AI-driven tools are being applied to design next- generation receptor constructs with improved precision and functionality
- Discuss the use of machine learning in identifying novel targets and accelerating preclinical discovery
- Highlight the challenges of obtaining sufficient, high-quality datasets
- Creating a third path to in-vivo CAR-T
- Highlight emerging preclinical evidence demonstrating feasibility and efficacy
New Data
